PharmaVentures increases its Asia-Pacific Presence

PharmaVentures are delighted to announce that Aki von Roy has joined as an Associate, based in Auckland, New Zealand. He has over 30 years experience in big pharma and 16 years in biotech. He has been involved in over 18 start-up or merger ventures as director or investor. 

PharmaVentures Advises MedGenesis in Agreement with Pfizer for Its Potential Therapy for Parkinson’s Disease

PharmaVentures is pleased to announce that it has acted as advisor to MedGenesis Therapeutix, Inc. (MedGenesis) in their recently announced agreement with Pfizer. MedGenesis' unique therapeutic approach, which will be used in the clinical development of potential treatments for Parkinson's disease, delivers GDNF (glial cell-derived neurotrophic factor) precisely to the regions of the brain where it is required via its convection enhanced delivery (CED) technology.

PharmaVentures strengthens its expertise in early stage deal making

PharmaVentures is pleased to announce the appointment of Dr Christopher Berry, formerly of Sanofi's R&D Transactions Group, as an Associate in the corporate advisory team. Based in Paris, France, Dr Berry has negotiated 56 signed deals since 2010. Partners included universities, biotechnology companies and large pharmaceutical companies.

PharmaVentures acts as exclusive advisor on the sale of Medical Insight to Karos Health

OXFORD, UK, August 27th, 2014

PharmaVentures is pleased to announce that it acted as exclusive advisor on the sale of Medical Insight, the Danish enterprise imaging software company, to Karos Health, based in Ontario, Canada. The sale was completed in June and announced yesterday by Karos Health.

PharmaVentures Divests Manufacturing Facility for Major Pharma Client

OXFORD, UK, July 7th, 2014

PharmaVentures is pleased to announce that it has acted as advisor to one of the top 10 Pharma companies in its divestment of a manufacturing facility in North America. The deal, finalised in May, represents a significant success for the major Pharma in implementing its forward strategy and the acquisition of a growth driving capability for the acquirer. This divestment follows multiple divestments of R&D and Manufacturing facilities in the last 4 years for several of the largest pharmaceutical companies.

PharmaVentures expands reach to Latin America

OXFORD, UK, May 21st, 2014

PharmaVentures is pleased to announce the appointment of Latin American expert Valeria Uribe as associate to significantly enhance the global reach of the Corporate Advisory team. 

PharmaVentures engaged in valuation of assets for newly AIM listed Tiziana Life Sciences.

OXFORD, UK, May 12th, 2014

PharmaVentures is pleased to announce that it has been engaged by Tiziana Life Sciences, Plc. to provide independent valuation advice for assets acquired as part of it's successful admission onto London Stock Exchange's AIM in April 2014.

Novartis appoints PharmaVentures as advisors on the future of its UK Horsham site

OXFORD, England, April 11th, 2014

PharmaVentures is pleased to announce that it has been appointed by Novartis as advisors on the future options for its UK Horsham site. 

PharmaVentures Strengthens M&A Team

OXFORD, UK, December 12th 2013

PharmaVentures is pleased to announce the appointment of expert industry executive Nigel Trim as an associate to significantly enhance PharmaVentures Corporate Advisory offering to the CRO space. 

PharmaVentures advised Nanosight on its sale to Spectris plc.

OXFORD, UK, September 30th, 2013 

PharmaVentures is pleased to announce that it has acted as exclusive M&A advisor to NanoSight in the successful sale of the company to Malvern Instruments, a Spectris plc company. Malvern completed the acquisition on 30th September 2013.

Pages

_

PharmaVentures talks to: